Table 1. Demographic and Clinical Characteristics of 31 Patients with Methamphetamine-Dependence Treated with CDP-choline or Placebo.
| CDP-choline group (n=16) | Placebo group (n=15) | p-value | |
|---|---|---|---|
| Age (years), mean±SD | 38.6±3.9 | 38.3±3.5 | 0.79 |
| Male, n (%) | 12 (75.0) | 11 (73.3) | 0.62 |
| Right handedness, n (%) | 14 (87.5) | 13 (86.7) | 0.68 |
| Education (years), mean±SD | 10.9±1.6 | 10.7±1.6 | 0.81 |
| Age at onset of MA use (years), mean±SD | 24.8±6.2 | 24.5±5.7 | 0.87 |
| Duration of MA use (months), mean±SD | 13.8±6.5 | 13.8±6.7 | 0.99 |
| Route of MA administration | |||
| Intravenous injection, n (%) | 16 (100) | 15 (100) | — |
| Average daily dose (g), mean±SD | 0.58±0.42 | 0.44±0.33 | 0.32 |
| Alcohol use, n (%) | |||
| Current alcohol abuse | 2 (12.5) | 3 (20.0) | — |
| Past history of alcohol dependence | 1 (6.3) | 2 (13.3) | |
| Marihuana use, n (%) | |||
| Current marihuana abuse or dependence | 5 (31.2) | 5 (33.3) | — |
| Smoking (pack year), mean±SD | 13.7±6.8 | 12.4±8.9 | 0.67 |
| Baseline HDRS scores, mean±SD | 12.3±7.5 | 13.6±5.3 | 0.57 |
Abbreviations: CDP-choline, cytidine-5′-diphosphate choline; MA, methamphetamine; HDRS, Hamilton Depression Rating Scale.